The Board of Malin presented the outcome of a strategic review of the business and provided an update on Malin’s vision, strategy, progress and outlook.
Ian Curley, Malin’s Executive Chairman, hosted the event with other members of the Malin team including Darragh Lyons, Chief Business and Financial Officer, and Dr Andrew von Eschenbach, Chief Medical Advisor. The event also included presentations on Malin’s four priority assets: Poseida Therapeutics, Kymab, Immunocore and Viamet, the portfolio companies which make up approximately 70% of Malin’s total portfolio fair value (as at 30 June 2018).
A replay of the webcast of the event is available by clicking the link below.
A copy of the agenda and presentations can also be downloaded below.